01 Integration of AI and 3D Tomosynthesis Integration of AI and 3D tomosynthesis in mammography workstations is a major trend in the global market. Healthcare providers are increasingly adopting AI-enabled systems that assist in lesion detection, risk assessment, and workflow optimization, improving diagnostic accuracy and efficiency. Additionally, 3D tomosynthesis support enhances early cancer detection rates. This trend reflects the market’s focus on advanced, user-friendly imaging solutions that streamline radiologist workflows and elevate the standard of breast cancer diagnostics.
02 Integration of AI in the Mammography Workstation A key trend in the global mammography workstation market is the growing integration of AI driven automation that enhances accuracy and reduces radiologist workload. Traditionally, mammography interpretation relied heavily on manual review, but advanced workstations now incorporate automated lesion detection, density assessment, and workflow triaging. These AI-enhanced capabilities are witnessing rapid adoption, improving diagnostic confidence while enabling faster, more consistent screening across diverse clinical environments.
April 2026 GE HealthCare expanded its collaboration with DeepHealth to extend global access to AI-powered breast screening solutions. The agreement integrates DeepHealth Breast Suite capabilities into mammography workflows to support radiologist interpretation and reading efficiency.
December 2025 DeepHealth launched its AI-powered Breast Suite for mammography workflows. The platform combines cancer detection, review, quality analytics, and intelligent reporting capabilities to support breast imaging interpretation.
November 2025 Siemens Healthineers introduced new contrast-enhanced mammography and biopsy capabilities for Mammomat B.brilliant. The enhancements support advanced image reconstruction and diagnostic breast imaging workflows.
July 2025 Clairity received U.S. FDA De Novo authorization for Clairity Breast, an AI-powered mammography platform that predicts five-year breast cancer risk from standard mammograms. The authorization supports integration of personalized risk assessment into breast imaging workflows.